Investigation announced for Investors in Kura Oncology, Inc. (NASDAQ: KURA) over potential Wrongdoing

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kura Oncology, Inc.

Investors who purchased shares of Kura Oncology, Inc. (NASDAQ: KURA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Kura Oncology, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Diego, CA based Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

On November 24, 2021, Kura Oncology, Inc. "announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold." Kura Oncology, Inc. advised that "[t]he partial clinical hold was initiated following the Company's recent report to the FDA of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML[,]" and that "[u]ntil the partial clinical hold is resolved, and the Company has more clarity regarding the impact on timing, Kura is suspending guidance on the completion of enrollment in the KOMET-001 Phase 1b study and determination of the recommended Phase 2 dose of KO-539."

Shares of Kura Oncology, Inc. (NASDAQ: KURA) declined from $19.72 per share on November 5, 2021, to as low as $11.49 per share on January 24, 2022.

Those who purchased shares of Kura Oncology, Inc. (NASDAQ: KURA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.